Summary

• 100% technical buy signals.
• 15 new highs and up 56.28% in the last month.
• 137.08% gain in the last year.

The Barchart Chart of the Day belongs to the biopharmaceutical company Paratek Pharmaceuticals (Nasdaq: PRTK).

Readers are always asking me how to find stocks that are just beginning to trend before everyone else discovers them. One of the best ways is to look at Barchart's Strong Volume Gains preformatted screener. It identifies stocks that have had significant increases in both volume and price over the past 5 days. Today it identified 100 stock that fitted that criteria. I sorted that list by the most frequent number of new highs in the last month then used the Flipchart feature to review the chart for consistent price appreciation. Since the Trend Spotter signaled a buy in 5/19 the stock gained 34.43%.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions, and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts. 

Barchart technical indicators:

• 100% technical buy signals
• 158.71+ Weighted Alpha
• 137.08% gain in the last year
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 15 new highs and up 56.28% in the last month
• Relative Strength Index 79.94%
• Technical support level at 9.91
• Recently traded at 11.04 with a 50 day moving average of 8.09

Fundamental factors:

• Market Cap $475 million
• Revenue expected to grow 270.10% this year and another 16.20% next year
• Earnings estimated to increase 92.00% this year and an additional 61.10% next year
• Wall Street analysts issued 6 strong buy and 3 buy recommendations on the stock
• Louis Navellier's Portfolio Graders give the stock a Quant Rating of B - Buy
• 7,380 investors are monitoring the stock on Seeking Alpha